MethylGene Inc. (TSX: MYG) a biopharmaceutical company focused on epigenetic regulation, today announced that it has enrolled its first patient in a single-agent Phase II clinical trial of its lead HDAC compound, MGCD0103, in patients with relapsed or refractory Hodgkin’s lymphoma, a cancer initially located in the lymph nodes. The initiation of this Phase II study results in milestone payments from the Company’s partners, Pharmion Corporation and Taiho Pharmaceutical, of U.S. $4.0 million and U.S. $1.5 million, respectively.
